



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Appl. No.: 10/533,744

Confirmation No.: Unknown

Applicant: Brown *et al.*

PCT Appl. No.: PCT/SE03/01703

National Phase Fld (371): May 4, 2005

PCT Filed: November 5, 2003

Docket No.: 100886-1P US

TC/A.U.: Unknown

Customer No.: 22466

Examiner: Unknown

Title: 4(Phenyl-Piperazinyl-Methyl) Benzamide Derivatives and Their Use for the Treatment of Pain or Gastrointestinal Disorders

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants submit herewith a list of patents and publications for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO/SB/08A and SB/08B forms.

*Considered 6/22/07*

Applicants also wish to make the Examiner aware of co-pending applications:

*EB*  
*↓*

10/714447, filed on Nov. 17, 2003;  
10/477642, a PCT national phase filed on May 16, 2002;  
10/533654, a PCT national phase filed on November 5, 2003; and  
10/533764, a PCT national phase filed on November 5, 2003.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

9

**Complete if Known**

Application Number	10/533,744
Filing Date	05/04/2005
First Named Inventor	William Brown
Art Unit	
Examiner Name	
Attorney Docket Number	100886-1P US

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
FB	A1	US- 3,940,386	02/24/1976	Szabo et al.	
	A2	US- 5,574,159	11/12/1996	Chang et al.	
	A3	US- 5,681,830	10/28/1997	Chang et al.	
	A4	US- 5,807,858	09/15/1998	Chang et al.	
	A5	US- 5,854,249	12/29/1998	Chang et al.	
	A6	US- 6,130,222	10/10/2000	Roberts et al.	
	A7	US- 6,680,318	01/20/2004	Brown et al.	
	A8	US- 6,680,321	01/20/2004	Roberts et al.	
	A9	US- 6,696,447	02/24/2004	Brown et al.	
	A10	US- 6,784,181	08/31/2004	Brown et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
FB	B1	WO 86/04584	08/14/1986	Aktiebolaget Leo		
	B2	WO 91/07967	06/13/1991	Janssen		
	B3	WO 01/74805	10/11/2001	AstraZeneca AB		
	B4	WO 93/15062	08/05/1993	The Wellcome		
	B5	WO 97/23466	07/03/1997	Astra Pharma Inc.		

Examiner  
Signature

F. Bernhardt

Date  
Considered

6/23/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet	2	of	9
-------	---	----	---

**Complete if Known**

Application Number	10/533,744
Filing Date	05/04/2005
First Named Inventor	William Brown
Art Unit	
Examiner Name	
Attorney Docket Number	100886-1P US

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>o</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
EB ↓	B6	WO	✓ 95/04051	02/09/1995	The Wellcome		
	B7	WO	✓ 98/28270	07/02/1998	Astra Aktiebolag		
	B8	WO	✓ 98/28275	07/02/1998	Astra Aktiebolag		
	B9	WO	✓ 99/33806	07/08/1999	Ortho-McNeil		
	B10	EP	✓ 0289227	11/02/1988	Syntex		

**Examiner  
Signature.**

*E. Beunhous*

Date  
Considered

6/23/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet	3	of	9
-------	---	----	---

**Complete if Known**

Application Number	10/533,744
Filing Date	05/04/2005
First Named Inventor	William Brown
Art Unit	
Examiner Name	
Attorney Docket Number	100886-1P US

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>d</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
LB ↓	B11	EP	0283310	09/21/1988	Sankyo Company		
	B12	EP	0166302	01/02/1986	Polindustria		
	B13	EP	0133323	02/20/1985	The Wellcome		
	B14	GB	2210366	06/07/1989	American Home		
	B15	GB	2076403	12/02/1981	Selvi & C.S.p.A.		

Examiner Signature	<i>F. Bernhardt</i>	Date Considered	6/23/07
-----------------------	---------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet	5	of	9
-------	---	----	---

**Complete if Known**

Application Number	10/533,744
Filing Date	05/04/2005
First Named Inventor	William Brown
Art Unit	
Examiner Name	
Attorney Docket Number	100886-1P US

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>o</sup>
		Country Code <sup>2</sup>	Number <sup>3</sup> Kind Code <sup>4</sup> (if known)				
LB ↓	B21	WO	✓ 92/04338	03/19/1992	The Up-John Co.		
	B22	EP	✓ 0624584	08/19/1998	Daiichi		
	B23	WO	✓ 02/094794	11/28/2002	AstraZeneca AB		
	B24	WO	✓ 01/45637	06/28/2001	AstraZeneca AB		
	B25	WO	✓ 01/46174	06/28/2001	AstraZeneca AB		

**Examiner  
Signature**

E Bernhard

**Date  
Considered**

6/23/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner, for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***

Application Number	10/533,744
Filing Date	05/04/2005
First Named Inventor	William Brown
Art Unit	
Examiner Name	
Attorney Docket Number	100886-1P US

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***

Substitute for form 1449B/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/533,744
				Filing Date	05/04/2005
				First Named Inventor	William Brown
				Art Unit	
				Examiner Name	
Sheet	7	of	9	Attorney Docket Number	100886-1P US

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
EB	C1	Bilsky et al., "SNC 80, A Selective, Nonpeptidic and Systemically Active Opioid Delta Agonist," J. Pharmacol. Experi. Ther. 273:359-366 (1995)		
	C2	Takemori et al., "Selective Naltrexone-Driven Opioid Receptor Antagonists," Annu. Rev. Pharmacol. Toxicol. 32:239-269 (1992)		
	C3	Bilsky et al., "Characterization of Enantiomers of (+) BW373U86 and Related Compounds: Highly Selective Non-Peptidic Delta Opioid Agonists," Reg. Peptides 54:25-26 (1994)		
	C4	Calderon et al., "Probes for Narcotic Receptor Mediated Phenomena. 19. Synthesis of ... Opioid Receptor Agonist," J. Med. Chem. 37:2125-2128 (1994)		
	C5	Calderon et al., "Probes for Narcotic Receptor Mediated Phenomena. 23. Synthesis ... Opioid Receptor Ligands," J. Med. Chem. 40:695-704 (1997)		
	C6	Chang et al., "A Novel, Potent and Selective Nonpeptidic Delta Opioid Receptor Agonist BW373U86," J. Pharmacol. Exper. Therap. 267:852-857 (1993)		
	C7	Katritzky et al., "Benzotriazole-Mediated Arylalkylation and Heteroarylalkylation," Chem. Soc. Rev. 23:363-373 (1994)		
	C8	Kingsbury et al., "Synthesis of Structural Analogs of Leukotriene B and their Receptor Binding Activity," J. Med. Chem. 36:3308-3320 (1993)		
	C9	Lopez et al., "Exploring the Structure-Activity Relationships... Opioid Receptor Nonpeptide Agonist Ligand," J. Med. Chem. 42:5359-5368 (1999)		
	C10	Plobeck et al., "New Diarylmethylpiperazines as Potent and Selective Nonpeptidic Opioid Receptor Agonists with Increased In Vitro Metabolic Stability," J. Med. Chem. 43:3878-3894 (2000)		

Examiner Signature	<i>E Bernhardt</i>	Date Considered	6/23/07
--------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/533,744
				Filing Date	05/04/2005
				First Named Inventor	William Brown
				Art Unit	
				Examiner Name	
Sheet	8	of	9	Attorney Docket Number	100886-1P US

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
F B	C11	Suggs et al., "Facile Synthesis fo 8-Substituted Quinolines," J. Org. Chem., 45:1514-1515 (1980)		
	C12	Zhang et al., "Probes for Narcotic Receptor Mediated Phenomena. 26. Synthesis ... Opioid Receptor Ligands," J. Med. Chem. 42:5455-5463 (1999)		
	C13	English Abstract for <del>Reference B16 on PTO/SB/08A, Page 4</del> FR 2696744 (1994)		
	C14	English Abstract for <del>Reference B17 on PTO/SB/08A, Page 4</del> DE 2431178 (1975)		
	C15	English Abstract for <del>Reference B18 on PTO/SB/08A, Page 4</del> DE 2900810 (1980)		
	C16	English Abstract for <del>Reference B19 on PTO/SB/08A, Page 4</del> JP 07138230 (1995)		
	C17	Burkey et al., "The Efficacy of Delta-Opioid Receptor-Selective Drugs," Medline Abstract for Life Sci. 62:1531-1536 (1998)		
	C18	Nagase et al., "The Pharmacological Profile of Delta Opioid Receptor Ligands, (+) and (-) TAN-67 on Pain Modulation," Medline Abstract for Life Sci. 68:2227-2231 (2001)		
	C19	Green, "Protective Groups in Organic Synthesis," pgs. 267-268 and 331 (1981)		
	10	C20	Abstract for HU 217619, <del>(A corresponding English language PCT application is cited as Reference B1 listed on PTO/SB/08A, Page 1</del> (2000).	

Examiner Signature	<i>F Bernhardt</i>	Date Considered	6/23/07
--------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 14498/PTO

**(Use as many sheets as necessary)**

**Complete If Known**

<b>Application Number</b>	10/533,744
<b>Filing Date</b>	05/04/2005
<b>First Named Inventor</b>	William Brown
<b>Art Unit</b>	
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	100886-1P US

Sheet	9	of	9
-------	---	----	---

### NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature	<i>F. Bernhardt</i>	Date Considered	6/23/07
-----------------------	---------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***